Fenofibrate to prevent amputation and reduce vascular complications in patients with diabetes: FENO-PREVENT
Main finding · Composite of LEA and PADResult — go to the resultHazard ratio 0.81 95% CI 0.70–0.94Authors' conclusion
This nationwide population-based retrospective observational study suggests that fenofibrate can prevent LEA and PAD in patients with T2D who are on statin therapy.
Study context
- Population
- Adults ≥20 years with T2D, Korean National Health Insurance Service Database (2009–2012)Propensity scores (PS)-matched 1:4
- Participants
- 114,920 adults
- Exposure
- Fenofibrate users vs non-users
- Fenofibraten = 22,984
- Non-usersn = 91,936reference
- Outcome
- Composite of:
- Lower extremity amputation (LEA)
- Peripheral arterial disease (PAD)
- Follow-up
- Median 7.6 years
Methodological detailsnationwide population-based, propensity-score matched 1:4
- Nationwide population-based
- Propensity-score matched 1:4
Main finding
As reported in the abstract
Hazard ratio
0.81
95% CI 0.70–0.94
Fenofibratevs Non-users
HR 0.81 (95% CI 0.70–0.94)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| LEA | 0.76 (0.60–0.96) | |
| PAD | 0.81 (0.68–0.96) | |
| 0.512Hazard ratio (log scale) |
Subgroups by age, gender and baseline lipid profile
- Consistent benefits across age groups, genders and baseline lipid profiles
Safety
Acute kidney injury, rhabdomyolysis, or hospitalization for these events
- No significant difference between the two groups
Original publication
Fenofibrate to prevent amputation and reduce vascular complications in patients with diabetes: FENO-PREVENT. Cardiovasc Diabetol. Published 3 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →